Publication at Faculty of Medicine in Hradec Králové |
2022
Abstract
Ofatumumab is a fully human anti-CD20 monoclonal antibody approved for the treatment of adult patients with active relapsing-remitting multiple sclerosis. It is the first self-administered B-cell therapy given monthly via subcutaneous injection at one's home.
Siponimod is registgered for treatment secondary progressive multiple sclerosis in Czech Republic. Siponimod is the first effective medicinal product for the treatment of patients with secondarty progressive multiple sclerosis which favorably affects both clinical and magnetic resonance parameters.
Three cas reports of MS patients treated which ofatumumab and siponimod are presented.